Vitreous Levels of Stromal Cell-Derived Factor 1 and Vascular Endothelial Growth Factor in Patients with Retinopathy of Prematurity

These findings confirm the increase in vitreous VEGF and SDF-1α levels in eyes with vascularly active stage 4 ROP. Anti-VEGF treatment may be of benefit in some eyes that develop ROP.